Presented by Matthew Matasar MD, Assistant Member of Lymphoma and Adult BMT Services, and Medical Director of the Lymphoma Survivorship Clinic at Memorial Sloan Kettering Cancer Center
Run time: 56 minute presentation, followed by 34 minute Q&A
Made possible, in part, by a grant from Seattle Genetics
Dr. Matasar discusses:
- History of Hodgkin lymphoma
- Reed Sternberg cells
- Incidence (number of new cases) of Hodgkin lymphoma each year
- Number of Hodgkin lymphoma survivors
- Signs and symptoms of Hodgkin lymphoma
- Stages of Hodgkin lymphoma
- Treatment of newly diagnosed Hodgkin lymphoma
- Treatment of relapsed or refractory Hodgkin lymphoma
- Autologous stem cell transplant for Hodgkin lymphoma (transplant using your own cells)
- Allogeneic stem cell transplant for Hodgkin lymphoma (transplant using donor cells)
- Factors to consider when choosing between an autologous or allogeneic transplant
- Current treatment options and results for patients with relapsed or refractory Hodgkin lymphoma
- New treatment options for patients with relapsed or refractory Hodgkin lymphoma including brentuximab, nivolumab and pembrolizumab
- Risks and benefits of transplant for patients with Hodgkin lymphoma
- Survivorship care plan for patients with Hodgkin lymphoma
